Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU trial of anti-amyloid/anti-tau disease-modifying treatment in dominantly inherited Alzheimer's disease
NL-OMON60430Phase 3Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of etalanetug, lecanemab and carbon-11 Pittsburgh compound B in Alzheimer's disease (AD) (4 arms), sponsored by Washington University School of Medicine. Primary endpoints: E2814 symptomatic cohort endpoint and E2814 asymptomatic cohort endpoint. Started May 2023; status: active, not recruiting.
02
Drugs
etalanetuglecanemabcarbon-11 Pittsburgh compound B
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60430.